title: Antiplatelet therapy from clinical trials to clinical practice.
abstract: A platelet-rich clot at the site of severe coronary stenosis, plaque erosion, or a recent plaque rupture is the common etiology of acute ischemic syndromes. Thus, antiplatelet therapy is the cornerstone in the management of these conditions. Aspirin in a dose ranging from 160 to 325 mg once daily should be administered to virtually all patients. In patients with severe disease, particularly those who have no acute angiography, clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi Pharmaceuticals) in a dose of 75 mg once daily should add to the benefit of aspirin for up to a year after the event. Clopidogrel also is an alternative to aspirin where a true aspirin allergy exists. Intravenous platelet glycoprotein IIb/IIIa receptor inhibitors demonstrated a robust benefit when used in conjunction with coronary intervention and thus far have no role in medical therapy alone. Oral platelet glycoprotein IIb/IIIa receptor inhibitors are of no clinical value.
authors.affiliation: Department of Cardiology, Marshfield Clinic, Marshfield, Wisconsin 54449, USA. rekalla.shereif@marshfieldclinic.org
authors.forename: Shereif H
authors.initials: SH
authors.lastname: Rezkalla
authors.forename: Michele
authors.initials: M
authors.lastname: Benz
mesh_terms: D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000188:drug therapy*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*
chemical_list: D010975:Platelet Aggregation Inhibitors